CL2023003063A1 - Agentes radioterapéuticos dirigidos al receptor de folato y su uso - Google Patents

Agentes radioterapéuticos dirigidos al receptor de folato y su uso

Info

Publication number
CL2023003063A1
CL2023003063A1 CL2023003063A CL2023003063A CL2023003063A1 CL 2023003063 A1 CL2023003063 A1 CL 2023003063A1 CL 2023003063 A CL2023003063 A CL 2023003063A CL 2023003063 A CL2023003063 A CL 2023003063A CL 2023003063 A1 CL2023003063 A1 CL 2023003063A1
Authority
CL
Chile
Prior art keywords
folate receptor
agents targeting
radiotherapeutic agents
present disclosure
targeting
Prior art date
Application number
CL2023003063A
Other languages
English (en)
Inventor
P Leamon Christopher
R Vlahov Iontcho
A Reddy Joseph
Krishna R Santhapuram Hari
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2023003063A1 publication Critical patent/CL2023003063A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a compuestos radioterapéuticos dirigidos al receptor de folato y su uso. La presente divulgación se refiere a conjugados radiomarcados para la obtención de imágenes dirigidos al receptor de folato y su uso. La presente divulgación además se refiere a composiciones farmacéuticas de los compuestos y conjugados que se describen en la presente, métodos de elaboración y métodos para utilizarlos.
CL2023003063A 2021-04-16 2023-10-12 Agentes radioterapéuticos dirigidos al receptor de folato y su uso CL2023003063A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163175883P 2021-04-16 2021-04-16

Publications (1)

Publication Number Publication Date
CL2023003063A1 true CL2023003063A1 (es) 2024-05-03

Family

ID=81384670

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003063A CL2023003063A1 (es) 2021-04-16 2023-10-12 Agentes radioterapéuticos dirigidos al receptor de folato y su uso

Country Status (15)

Country Link
US (1) US20240252693A1 (es)
EP (1) EP4323017A1 (es)
JP (1) JP2024516797A (es)
KR (1) KR20230171964A (es)
CN (1) CN117083088A (es)
AR (1) AR125353A1 (es)
AU (1) AU2022257363A1 (es)
BR (1) BR112023021189A2 (es)
CA (1) CA3214074A1 (es)
CL (1) CL2023003063A1 (es)
CO (1) CO2023013494A2 (es)
IL (1) IL307499A (es)
MX (1) MX2023012114A (es)
TW (1) TW202304518A (es)
WO (1) WO2022219569A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
ES2171392T3 (es) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US9265746B2 (en) * 2006-05-31 2016-02-23 Merck & Cie Method for cell-specific targeting
RU2497825C1 (ru) * 2012-07-03 2013-11-10 Государственное Научное Учреждение "Институт Физики Имени Б.И. Степанова Национальной Академии Наук Беларуси" Конъюгат фолиевой кислоты и способ его получения
SG11201502896XA (en) * 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
US9365599B2 (en) * 2012-10-26 2016-06-14 Korea Atomic Energy Research Institute N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient
WO2015073678A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
WO2016168471A1 (en) * 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
CN112142739A (zh) * 2020-10-21 2020-12-29 上海交通大学医学院附属仁济医院 靶向叶酸受体的放射性叶酸衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CA3214074A1 (en) 2022-10-20
AU2022257363A1 (en) 2023-10-12
KR20230171964A (ko) 2023-12-21
AR125353A1 (es) 2023-07-12
US20240252693A1 (en) 2024-08-01
IL307499A (en) 2023-12-01
CO2023013494A2 (es) 2023-10-30
EP4323017A1 (en) 2024-02-21
TW202304518A (zh) 2023-02-01
CN117083088A (zh) 2023-11-17
BR112023021189A2 (pt) 2024-02-06
JP2024516797A (ja) 2024-04-17
MX2023012114A (es) 2023-10-24
WO2022219569A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
NI202000078A (es) Compuestos heteroaril tetracíclicos
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
GT201300025A (es) Derivados anticancerosos, su preparación y su aplicación en terapeútica
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
CR11106A (es) Inhibidores de cinasa p710 s6
PE20201464A1 (es) Conjugados anticuerpo anti-cd40-farmaco
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
CL2024000282A1 (es) Herboxidieno de conjugados de anticuerpo - fármaco y métodos de uso (divisional).
HN2009003357A (es) Nuevos compuesto ligandos del receptor de la adenosina a3
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
UY38540A (es) Compuestos de fenilamidina 3-sustituida, preparación y uso
BR112016011417A8 (pt) derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CL2022000319A1 (es) Derivados de amidas híbridas de anfotericina b